title: Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making.
authors.affiliation: *Department of Medical Oncology, University Medical Center Utrecht, Utrecht †Department of Medical Oncology, Academic Medical Center, University of Amsterdam Amsterdam, The Netherlands.
authors.forename: Mira D
authors.initials: MD
authors.lastname: Franken
authors.forename: Miriam
authors.initials: M
authors.lastname: Koopman
authors.forename: Martijn G H
authors.initials: MG
authors.lastname: van Oijen
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D000068818:Cetuximab / Q000191:economics* / Q000627:therapeutic use*; D000066491:Clinical Decision-Making; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000191:economics*; D003362:Cost-Benefit Analysis; D005472:Fluorouracil / Q000191:economics / Q000627:therapeutic use; D002955:Leucovorin / Q000191:economics / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years
chemical_list: D000970:Antineoplastic Agents; D000068818:Cetuximab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin